Security key
45339J105
Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value (INDP)
CUSIP: 45339J105
Q3 2022 13F Holders as of 30 Sep 2022
- Type / Class
- Equity / Common Stock, $0.01 par value
- Shares outstanding
- 113,183,288
- Total 13F shares
- 566,356
- Share change
- +66,011
- Total reported value
- $1,222,000
- Price per share
- $2.17
- Number of holders
- 12
- Value change
- +$141,749
- Number of buys
- 6
- Number of sells
- 4
Report period
Q3 2022
Institutions
12
Top holders
10
INDP full security history
Newer quarter: Q4 2022
Previous quarter: Q2 2022
Indaptus Therapeutics, Inc. SEC filings
Indaptus Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 45339J105
Recent filing periods:
Top shareholders of INDP - Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
|
Company |
0.22%
|
246,947
|
$645,000 | — | 30 Jun 2022 | |
| INVESTMENT HOUSE LLC |
13F
|
Company |
0.08%
|
95,629
|
$250,000 | — | 30 Jun 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.05%
|
52,475
|
$136,000 | — | 30 Jun 2022 | |
| Stratos Wealth Partners, LTD. |
13F
|
Company |
0.02%
|
26,832
|
$70,000 | — | 30 Jun 2022 | |
| Vivaldi Capital Management LP |
13F
|
Company |
0.02%
|
24,000
|
$63,000 | — | 30 Jun 2022 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.02%
|
19,600
|
$51,000 | — | 30 Jun 2022 | |
| STATE STREET CORP |
13F
|
Company |
0.02%
|
19,473
|
$51,000 | — | 30 Jun 2022 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.01%
|
10,296
|
$27,000 | — | 30 Jun 2022 | |
| Harel Insurance Investments & Financial Services Ltd. |
13F
|
Company |
0%
|
2,888
|
$7,000 | — | 30 Jun 2022 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
1,705
|
$4,000 | — | 30 Jun 2022 | |
| NATIONAL BANK OF CANADA /FI/ |
13F
|
Company |
0%
|
500
|
$1,000 | — | 30 Jun 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
365
|
$1,000 | — | 30 Jun 2022 | |
| Hoonmo Lee |
3/4/5
|
Director |
—
mixed-class rows
|
708,272
mixed-class rows
|
$1,626,157 | — | 04 Aug 2021 | |
| Boyan Vesselinov Litchev |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
1,150
|
$2,691 | — | 01 Feb 2022 | |
| Brian O'Callaghan |
3/4/5
|
Director |
—
class O/S missing
|
13,750
|
$976 | — | 30 Sep 2022 |
Institutional Holders of Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value (INDP) as of Q3 2022
As of 30 Sep 2022,
Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value (INDP) was held by
12 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
566,356 shares.
The largest 10 holders included
VANGUARD GROUP INC, INVESTMENT HOUSE LLC, STRATEGY ASSET MANAGERS LLC, GEODE CAPITAL MANAGEMENT, LLC, Stratos Wealth Partners, LTD., Vivaldi Capital Management LP, RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP, NORTHERN TRUST CORP, and CITADEL ADVISORS LLC.
This page lists
12
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2022 vs Q2 2022 Across Filers
Q2 2022 holders
12
Q3 2022 holders
12
Holder diff
0
| Investor | Q2 2022 Shares | Q3 2022 Shares | Share Diff | Share Chg % | Q2 2022 Value $ | Q3 2022 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.